First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center

Frontiers in Pharmacology
Bin WangHui-Qing Chen

Abstract

The response to pazopanib in patients with metastatic renal cell carcinoma (mRCC) has been found to differ in Western and Eastern populations. Here, we analyzed the efficacy and side effects of pazopanib as first-line therapy in 31 consecutive patients with mRCC who were treated at a single Chinese center. Thirty-one consecutive patients with mRCC (20 males and 11 females, median age 59 years) were treated with pazopanib between October 2017 and July 2019. All patients had received a pathological diagnosis of RCC by prior radical nephrectomy or biopsy. All cases were treated with pazopanib (800 mg/day orally) as first-line therapy. Administration was continued until disease progression or unacceptable toxicities occurred. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety were evaluated. Twenty-nine patients were eligible for final analysis. At the median follow-up of 12.7 months, 34.5% (10/29) patients achieved a partial response (PR), 41.4% (12/29) patients had stable disease (SD), seven (24.1%) patients had disease progression (PD), and one patient had died. The ORR and DCR were 34.5% and 75.9%, respectively, and the median PFS was 10.1 months (95% co...Continue Reading

References

Oct 29, 2010·Clinical Medicine Insights. Oncology·Joshua M Lang, Michael R Harrison
Nov 5, 2014·Cancer Metastasis Reviews·J Michael RandallRazelle Kurzrock
Feb 3, 2016·Therapeutic Advances in Urology·David Cella, Jennifer L Beaumont
Aug 4, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jose Manuel Ruiz-MoralesDaniel Y C Heng
May 19, 2017·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Aly-Khan A LalaniNaveen S Basappa
Apr 15, 2018·Clinical Genitourinary Cancer·Jinhee ParkNicholas J Vogelzang
Nov 28, 2018·BMC Pharmacology & Toxicology·María José Méndez-VidalEnrique Gallardo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.